You can accept or revoke the cookies used on this website at any time with the selection below or by adjusting your cookie settings. For complete details about our cookies, see our Cookie Policy.
Ultra-sensitive NGS-based liquid biopsy technology in CDx
QIAGEN and Sysmex Inostics have recently announced a global alliance for the development and commercialization of cancer companion diagnostics (CDx). The partnership capitalizes on Sysmex Inostics’ Plasma-Safe-SeqS (SafeSEQ), an ultra-sensitive next generation sequencing (NGS) liquid biopsy technology and leverages QIAGEN’s experience in developing and commercializing companion diagnostics.
Learn more about:
Embracing opportunity through the QIAGEN-Sysmex partnership
The Power of SafeSEQ: Technology and performance overview
Realizing the clinical value of ultra-sensitive technology